Ligand Pharmaceuticals Inc. | Ownership
Companies that own Ligand Pharmaceuticals Inc.
BlackRock Fund Advisors
3,076,419
14.58%
230,830
0.04%
06/30/2018
The Vanguard Group, Inc.
1,979,518
9.38%
78,011
0.02%
06/30/2018
William Blair Investment Management LLC
1,275,069
6.04%
113,742
0.61%
06/30/2018
Henderson Global Investors Ltd.
927,101
4.38%
54,990
0.11%
06/30/2018
SSgA Funds Management, Inc.
910,727
4.32%
-39,562
0.02%
06/30/2018
Victory Capital Management, Inc.
537,355
2.54%
27,075
0.27%
06/30/2018
Renaissance Technologies LLC
523,494
2.48%
159,100
0.14%
06/30/2018
Conestoga Capital Advisors LLC
501,894
2.38%
31,364
3.7%
06/30/2018
Fidelity Management & Research Co.
440,584
2.09%
14,017
0.01%
06/30/2018
Cardinal Capital Management LLC
425,237
2.02%
-14,098
3.45%
06/30/2018
| Address |
3911 Sorrento Valley Boulevard
San Diego California 92121
United States
|
|
Employees
|
- |
| Website |
http://www.ligand.com |
| Updated |
07/08/2019 |
| Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. |
